EAM Investors LLC Has $788,000 Position in Delcath Systems, Inc. (NASDAQ:DCTH)

EAM Investors LLC lessened its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 25.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 65,447 shares of the company's stock after selling 22,759 shares during the period. EAM Investors LLC owned about 0.20% of Delcath Systems worth $788,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of DCTH. Quantbot Technologies LP acquired a new stake in Delcath Systems during the 4th quarter worth about $66,000. Geode Capital Management LLC lifted its position in shares of Delcath Systems by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock valued at $2,275,000 after acquiring an additional 7,298 shares in the last quarter. Riverwater Partners LLC boosted its stake in Delcath Systems by 46.2% in the 4th quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock worth $328,000 after purchasing an additional 8,601 shares during the period. State Street Corp lifted its holdings in shares of Delcath Systems by 12.4% in the third quarter. State Street Corp now owns 85,457 shares of the company's stock valued at $772,000 after purchasing an additional 9,400 shares in the last quarter. Finally, Barclays PLC acquired a new stake in shares of Delcath Systems in the third quarter worth $104,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Stock Performance

Shares of Delcath Systems stock traded up $0.21 during midday trading on Tuesday, reaching $11.55. 36,322 shares of the company's stock traded hands, compared to its average volume of 353,626. The company has a market cap of $385.98 million, a price-to-earnings ratio of -8.57 and a beta of 0.85. Delcath Systems, Inc. has a 52 week low of $4.87 and a 52 week high of $16.97. The company's 50 day simple moving average is $13.04 and its 200 day simple moving average is $12.33.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. During the same period in the prior year, the company posted ($0.48) EPS. As a group, equities research analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on DCTH shares. HC Wainwright increased their price objective on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Craig Hallum boosted their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Delcath Systems currently has an average rating of "Moderate Buy" and a consensus price target of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.